Suitability of Xpert MTB/RIF and Genotype MTBDR plus for Patient Selection for a Tuberculosis Clinical Trial
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Participation criteria for clinical trials in pulmonary tuberculosis commonly include confirmation of sputum positive for mycobacteria and an indication of drug susceptibility before treatment is initiated. We investigated the suitability of two novel sputum-based nucleic acid amplification methods for patient selection in a recent early bactericidal activity study. Spontaneously expectorated sputum samples of 140 consecutive pulmonary tuberculosis patients were examined with direct fluorescence microscopy, Genotype MTBDR plus assay (MTBDR), Xpert MTB/RIF assay (Xpert), and liquid mycobacterial culture. The methods detected mycobacteria or mycobacterial DNA in 96.8%, 90.5%, 92.9%, and 92.1% of samples, respectively. MTBDR, Xpert, and liquid culture were 100% concordant for detection of resistance to rifampin. Sensitivity and specificity of MTBDR for detection of isoniazid resistance were 83.3% and 100%, respectively. For quantification of mycobacterial sputum load, we found a correlation between Xpert DNA amplification cycle thresholds, time to positivity, and microscopy smear grade. The best correlation was found between Xpert and time to positivity ( r = 0.54), which were both correlated with smear microscopy with r values equal to −0.40 and −0.48, respectively. We conclude that MTBDR and Xpert are suitable screening tools for determining rifampin resistance in sputum microscopy smear-positive patients before participation in tuberculosis trials. Xpert should be further explored as a surrogate measurement for sputum mycobacterial load.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309 · cited 3×
“Xpert has recently been validated as a diagnostic test for pulmonary TB (4).”
BackgroundMethodHelb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01463-09 · Cited by 914 · cited 1×
“Another example is the Xpert MTB/RIF assay (Xpert; Cepheid; Sunnyvale, CA), employing a fully automated real-time PCR mixture contained in a disposable cartridge (13).”
MethodEvaluation of the analytical performance of the Xpert MTB/RIF assay
Blakemore, R., Story, E., Helb, D., Kop, J., Banada, P., Owens, M. R., Chakravorty, S., Jones, M., & Alland, D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00128-10 · Cited by 485 · cited 3×
“The CT of probe B was used as a quantitative measurement as previously described elsewhere (3).”
Method
Cited by
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
Steingart, K. R., Schiller, I., Horne, D. J., Pai, M., Boehme, C. C., & Dendukuri, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub3 · Cited by 1,102
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
Dorman, S. E., Nahid, P., Kurbatova, E. V., Phillips, P. P. J., Bryant, K., Dooley, K. E., Engle, M., Goldberg, S. V., Phan, H. T. T., Hakim, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2033400 · Cited by 539
Lawn, S. D., & Nicol, M. P. (2011) · Future Microbiology · doi:10.2217/fmb.11.84 · Cited by 486
Nicol, M. P., Workman, L., Isaacs, W., Munro, J., Black, F., Eley, B., Boehme, C. C., Zemanay, W., & Zar, H. J. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70167-0 · Cited by 338
Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis
Tortoli, E., Russo, C., Piersimoni, C., Mazzola, E., Dal Monte, P., Pascarella, M., Borroni, E., Mondo, A., Piana, F., Scarparo, C., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00176311 · Cited by 322
“There is a large number of studies evaluating Xpert on pulmonary specimens [5,6,17-23]; the sensibility varies from 95 to 100% in smear-positive sputa, and from 47 to 77% in smearnegative ones.”
Background
Metadata
- Authors
- Friedrich, S. O., Venter, A., Kayigire, X. A., Dawson, R., Donald, P. R., & Diacon, A. H.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2011-08
- Volume
- 49
- Issue
- 8
- Pages
- 2827-2831
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2083262622
- Cited by
- 40
- References
- 4
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suitability of Xpert MTB/RIF and Genotype MTBDR plus for Patient Selection for a Tuberculosis Clinical Trial. https://app.cochat.ai/papers/10.1128/jcm.00138-11
- The paper
- Friedrich, S. O., Venter, A., Kayigire, X. A., Dawson, R., Donald, P. R., & Diacon, A. H. (2011). Suitability of Xpert MTB/RIF and Genotype MTBDR plus for Patient Selection for a Tuberculosis Clinical Trial. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00138-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.